Dr. Sanjay Razdan, MD

Dr. Razdan practices at HCA Florida Kendall Hospital in Miami, Florida, part of HCA Healthcare.

Dr. Razdan's NPI, 1518921865, was assigned on April 13, 2006. Dr. Razdan graduated from G.S.V.M Medical College Kanpur in 1984. Dr. Razdan holds Florida license ME81109.

Dr. Razdan's primary practice is HCA Florida Kendall Hospital, at 11750 Bird Rd, Miami, FL 33175 in Miami-Dade County. The practice phone is (305) 223-3000.

Dr. Razdan's primary practice is HCA Florida Kendall Hospital in Miami, Florida, part of HCA Healthcare. The medical group on file is SSR Consultants. Dmand AI also links Dr. Razdan to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Razdan practices, 2 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Razdan's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Razdan is board certified in urology by the American Board of Urology. Dmand AI has Dr. Razdan's licenses on file in 3 states: Florida, Pennsylvania and Michigan.

Dmand AI lists enlarged prostate, enlarged prostate transurethral surgery (TURP), erectile dysfunction, kidney removal surgery, kidney stone disease, prostate surgery, urinary endoscopy and UTI among the conditions Dr. Razdan treats.

CMS data shows 656 Medicare services from Dr. Razdan across 10 procedure codes in 2024, for 237 Medicare patients. Medicare paid $96,007 for them.

CMS counts 237 Medicare patients who saw Dr. Razdan in 2024. The largest group is 65 to 74, with 105 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 44% are also on Medicaid. Their average risk score is 2.25, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Razdan's median patient age at 64, with 14% women.

In 2024, Dr. Razdan wrote 861 Medicare Part D claims for 293 patients. 91% of them were for generic drugs. CMS names the drug for 824 of them, across 13 drugs with 11 or more claims each, at $53,638 in total drug cost. In 2023, CMS named 804 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Razdan for performance year 2024, reported individually. Dr. Razdan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 24 procedures of prostate resection by Dr. Razdan, more than 86% of the clinicians it reports for that procedure.

Dmand AI links 42 papers to Dr. Razdan, published from 2009 to 2025. 2018 was the busiest year, with 4. The most frequent topics are Prostatectomy, Prostatic Neoplasms and Laparoscopy. Dr. Razdan has published most often in J Endourol. Dr. Razdan's most frequent co-authors are Shirin Razdan, MD, Rajesh R. Bajpai, MD and Robert A. Edelstein, MD.

CMS Open Payments shows 333 general payments to Dr. Razdan from 51 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 45% of the total. AxoGen paid the most, $9,242.

Dmand AI lists 33 awards for Dr. Razdan, most recently Health Care Heroes Award 2018 in 2018.

Dr. Razdan graduated from G.S.V.M Medical College Kanpur in 1984.

Dr. Razdan is in network with 14 carriers, including Aetna, United Healthcare and Elevance. HMO plans come from the most carriers, 9. Check the plan with the practice before a visit.